Numoda Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Philadelphia PA United States (1996)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2009
NCT00865319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Numoda (0) Acquired (1)

ocriplasmin (jetrea) (2 trials)

Drugs in Phase 2 Trials (2)

99mtc ecdg (2 trials)

fludeoxyglucose f-18 (2 trials)

Drugs in Phase 1 Trials (3)

99mtc ethylenedicysteine-deoxyglucose (1 trial)

plerixafor (mozobil) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

End Stage Liver Disease (Phase 1)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 6